CV: Edema; weight gain; CHF; altered BP; palpitations; chest pain; bradycardia; tachycardia.
CNS: Headache; vertigo; drowsiness; dizziness; insomnia.
DERM: Rash; urticaria; purpura.
EENT: Blurred vision; tinnitus; salivation; glossitis.
GI: Diarrhea; dry mouth; vomiting; abdominal pain; dyspepsia; GI bleeding; nausea; constipation; flatulence.
GU: Hematuria; proteinuria; dysuria; renal failure.
HEMA: Decreased hematocrit; bleeding; neutropenia; leukopenia; pancytopenia; eosinophilia; thrombocytopenia.
HEPA: Mild elevations in LFT results.
RESP: Bronchospasm; laryngeal edema; rhinitis; dyspnea; pharyngitis; hemoptysis; shortness of breath.
OTHER: Autoimmune hemolytic anemia may occur if used long term.
Increased risk of gastric erosion and bleeding.
Nephrotoxicity of both agents may be increased.
Exercise caution when coadministering mefenamic acid with drugs known to inhibit the isoenzyme 2C9.
Serum lithium levels may be increased.
Increased methotrexate levels.
Additive GI toxicity.
Therapeutic Classification: NSAID
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal